Therapeutic delivery of recombinant glucocerebrosidase enzyme-containing extracellular vesicles to human cells from Gaucher disease patients.
Extracellular vesicles
Gaucher disease
Glucocerebrosidase
HEK293T cell
Lentiviral vector
Macrophages
Neurons
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
received:
16
02
2024
accepted:
22
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
2
10
2024
Statut:
epublish
Résumé
Gaucher disease (GD) is one of the most common types of lysosomal storage diseases (LSDs) caused by pathogenic variants of lysosomal β-glucocerebrosidase gene (GBA1), resulting in the impairment of Glucocerebrosidase (GCase) enzyme function and the accumulation of a glycolipid substrate, glucosylceramide (GlcCer) within lysosomes. Current therapeutic approaches such as enzyme replacement therapy and substrate reduction therapy cannot fully rescue GD pathologies, especially neurological symptoms. Meanwhile, delivery of lysosomal enzymes to the endocytic compartment of affected human cells is a promising strategy for treating neuropathic LSDs. Here, we describe a novel approach to restore GCase enzyme in cells from neuropathic GD patients by producing extracellular vesicle (EVs)-containing GCase from cells overexpressing GBA1 gene. Lentiviral vectors containing modified GBA1 were introduced into HEK293T cells to produce a stable cell line that provides a sustainable source of functional GCase enzyme. The GBA1-overexpressing cells released EV-containing GCase enzyme, that is capable of entering into and localizing in the endocytic compartment of recipient cells, including THP-1 macrophage, SH-SY5Y neuroblastoma, and macrophages and neurons derived from induced pluripotent stem cells (iPSCs) of neuropathic GD patients. Importantly, the recipient cells exhibit higher GCase enzyme activity. This study presents a promising therapeutic strategy to treat severe types of LSDs. It involves delivering lysosomal enzymes to the endocytic compartment of human cells affected by conditions such as GDs with neurological symptoms, as well as potentially other neurological disorders impacting lysosomes.
Sections du résumé
BACKGROUND
BACKGROUND
Gaucher disease (GD) is one of the most common types of lysosomal storage diseases (LSDs) caused by pathogenic variants of lysosomal β-glucocerebrosidase gene (GBA1), resulting in the impairment of Glucocerebrosidase (GCase) enzyme function and the accumulation of a glycolipid substrate, glucosylceramide (GlcCer) within lysosomes. Current therapeutic approaches such as enzyme replacement therapy and substrate reduction therapy cannot fully rescue GD pathologies, especially neurological symptoms. Meanwhile, delivery of lysosomal enzymes to the endocytic compartment of affected human cells is a promising strategy for treating neuropathic LSDs.
RESULT
RESULTS
Here, we describe a novel approach to restore GCase enzyme in cells from neuropathic GD patients by producing extracellular vesicle (EVs)-containing GCase from cells overexpressing GBA1 gene. Lentiviral vectors containing modified GBA1 were introduced into HEK293T cells to produce a stable cell line that provides a sustainable source of functional GCase enzyme. The GBA1-overexpressing cells released EV-containing GCase enzyme, that is capable of entering into and localizing in the endocytic compartment of recipient cells, including THP-1 macrophage, SH-SY5Y neuroblastoma, and macrophages and neurons derived from induced pluripotent stem cells (iPSCs) of neuropathic GD patients. Importantly, the recipient cells exhibit higher GCase enzyme activity.
CONCLUSION
CONCLUSIONS
This study presents a promising therapeutic strategy to treat severe types of LSDs. It involves delivering lysosomal enzymes to the endocytic compartment of human cells affected by conditions such as GDs with neurological symptoms, as well as potentially other neurological disorders impacting lysosomes.
Identifiants
pubmed: 39358794
doi: 10.1186/s13023-024-03376-7
pii: 10.1186/s13023-024-03376-7
doi:
Substances chimiques
Glucosylceramidase
EC 3.2.1.45
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
363Informations de copyright
© 2024. The Author(s).
Références
Baris HN, Cohen IJ, Mistry PK. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev. 2014;12(Suppl 10 1):72–81.
pubmed: 25345088
pmcid: 4520262
Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, et al. Gaucher Disease in bone: from pathophysiology to practice. J Bone Min Res. 2019;34(6):996–1013.
doi: 10.1002/jbmr.3734
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C et al. A review of Gaucher Disease Pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2).
Blauwendraat C, Tayebi N, Woo EG, Lopez G, Fierro L, Toffoli M, et al. Polygenic Parkinson’s Disease Genetic Risk score as risk modifier of parkinsonism in Gaucher Disease. Mov Disord. 2023;38(5):899–903.
doi: 10.1002/mds.29342
pubmed: 36869417
pmcid: 10271962
Wilke M, Poswar F, Borelli WV, Michelin Tirelli K, Randon DN, Lopes FF, et al. Follow-up of pre-motor symptoms of Parkinson’s disease in adult patients with gaucher disease type 1 and analysis of their lysosomal enzyme profiles in the CSF. Orphanet J Rare Dis. 2023;18(1):309.
doi: 10.1186/s13023-023-02875-3
pubmed: 37784132
pmcid: 10546662
Linari S, Castaman G. Clinical manifestations and management of Gaucher disease. Clin Cases Min Bone Metab. 2015;12(2):157–64.
Mistry PK, Lopez G, Schiffmann R, Barton NW, Weinreb NJ, Sidransky E. Gaucher disease: Progress and ongoing challenges. Mol Genet Metab. 2017;120(1–2):8–21.
doi: 10.1016/j.ymgme.2016.11.006
pubmed: 27916601
Lee KO, Luu N, Kaneski CR, Schiffmann R, Brady RO, Murray GJ. Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain. Biochem Biophys Res Commun. 2005;337(2):701–7.
doi: 10.1016/j.bbrc.2005.05.207
pubmed: 16223608
Gramlich PA, Westbroek W, Feldman RA, Awad O, Mello N, Remington MP, et al. A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: design, production, and assessment. J Biotechnol. 2016;221:1–12.
doi: 10.1016/j.jbiotec.2016.01.015
pubmed: 26795355
pmcid: 5381155
Muro S. New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(2):189–204.
doi: 10.1002/wnan.73
pubmed: 20112244
pmcid: 4002210
Chauhan K, Olivares-Medina CN, Villagrana-Escareno MV, Juarez-Moreno K, Cadena-Nava RD, Rodriguez-Hernandez AG, et al. Targeted enzymatic VLP-Nanoreactors with beta-glucocerebrosidase activity as potential enzyme replacement therapy for Gaucher’s Disease. ChemMedChem. 2022;17(19):e202200384.
doi: 10.1002/cmdc.202200384
pubmed: 35918294
pmcid: 9804995
Gonzalez-Davis O, Villagrana-Escareno MV, Trujillo MA, Gama P, Chauhan K, Vazquez-Duhalt R. Virus-like nanoparticles as enzyme carriers for enzyme replacement therapy (ERT). Virology. 2023;580:73–87.
doi: 10.1016/j.virol.2023.01.017
pubmed: 36791560
Sutaria DS, Badawi M, Phelps MA, Schmittgen TD. Achieving the Promise of Therapeutic Extracellular vesicles: the Devil is in details of therapeutic loading. Pharm Res. 2017;34(5):1053–66.
doi: 10.1007/s11095-017-2123-5
pubmed: 28315083
pmcid: 5565485
van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–28.
doi: 10.1038/nrm.2017.125
pubmed: 29339798
Ramos-Zaldivar HM, Polakovicova I, Salas-Huenuleo E, Corvalan AH, Kogan MJ, Yefi CP, et al. Extracellular vesicles through the blood-brain barrier: a review. Fluids Barriers CNS. 2022;19(1):60.
doi: 10.1186/s12987-022-00359-3
pubmed: 35879759
pmcid: 9310691
Matsumoto J, Stewart T, Banks WA, Zhang J. The transport mechanism of Extracellular vesicles at the blood-brain barrier. Curr Pharm Des. 2017;23(40):6206–14.
doi: 10.2174/1381612823666170913164738
pubmed: 28914201
Kangboonruang K, Pornsukjantra T, Tong-Ngam P, Chokpanuwat T, Tim-Aroon T, Wattanasirichaigoon D, et al. Establishment of MUi030-A: a human induced pluripotent stem cell line carrying homozygous L444P mutation in the GBA1 gene to study type-3 gaucher disease. Stem Cell Res. 2023;73:103229.
doi: 10.1016/j.scr.2023.103229
pubmed: 37890332
Pornsukjantra T, Kangboonruang K, Tong-Ngam P, Tim-Aroon T, Wattanasirichaigoon D, Anurathapan U, et al. A generation of human induced pluripotent stem cell line (MUi031-A) from a type-3 gaucher disease patient carrying homozygous mutation on GBA1 gene. Stem Cell Res. 2022;60:102698.
doi: 10.1016/j.scr.2022.102698
pubmed: 35151019
Tangprasittipap A, Jittorntrum B, Wongkummool W, Kitiyanant N, Tubsuwan A. Generation of induced pluripotent stem cells from peripheral blood CD34 + hematopoietic progenitors of a 31year old healthy woman. Stem Cell Res. 2017;20:91–3.
doi: 10.1016/j.scr.2017.02.013
pubmed: 28395748
Cui D, Franz A, Fillon SA, Jannetti L, Isambert T, Fundel-Clemens K, et al. High-yield Human Induced Pluripotent Stem Cell-Derived monocytes and macrophages are functionally comparable with primary cells. Front Cell Dev Biol. 2021;9:656867.
doi: 10.3389/fcell.2021.656867
pubmed: 33937256
pmcid: 8080307
Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.
doi: 10.1080/20013078.2018.1535750
pubmed: 30637094
pmcid: 6322352
Gehrlein A, Udayar V, Anastasi N, Morella ML, Ruf I, Brugger D, et al. Targeting neuronal lysosomal dysfunction caused by beta-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat Commun. 2023;14(1):2057.
doi: 10.1038/s41467-023-37632-4
pubmed: 37045813
pmcid: 10097658
Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE, et al. Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev. 2020;159:332–43.
doi: 10.1016/j.addr.2020.04.004
pubmed: 32305351
Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, et al. Long-term effectiveness of enzyme replacement therapy in children with gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):961–8.
doi: 10.1007/s10545-014-9693-8
pubmed: 24638276
Charrow J, Scott CR. Long-term treatment outcomes in Gaucher disease. Am J Hematol. 2015;90(Suppl 1):S19–24.
pubmed: 26096742
Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, et al. Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol. 2008;64(5):514–22.
doi: 10.1002/ana.21491
pubmed: 19067373
pmcid: 2605167
Donald A, Bjorkvall CK, Vellodi A, Consortium G, Cox TM, Hughes D, et al. Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic gaucher disease. Orphanet J Rare Dis. 2022;17(1):234.
doi: 10.1186/s13023-022-02378-7
pubmed: 35717194
pmcid: 9206376
Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
doi: 10.3402/jev.v4.27066
pubmed: 25979354
Sivanantham A, Jin Y. Impact of Storage conditions on EV Integrity/Surface markers and cargos. Life (Basel). 2022;12(5).